Get started
Author

Kimberly Umans

Observed names: K. Umans, Umans, Kimberly
ORCID: 0009-0006-2717-8265
Observed ORCID: 0009-0006-2717-8265
OpenAlex ID: A5004417493
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
2021 · Stephen Salloway, Spyros Chalkias, et al. · JAMA Neurology · 661
PDF
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
2016 · Gavin Giovannoni, Ludwig Kappos, et al. · Multiple Sclerosis and Related Disorders · 55
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
2016 · Ralf Gold, Ernst-Wilhelm Radue, et al. · BMC Neurology · 47
PDF
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
2023 · Stephanie J. Loomis, Ryan Miller, et al. · Neurology · 44
PDF
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study
2013 · Eva Havrdova, Gavin Giovannoni, et al. · Multiple Sclerosis Journal · 32
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
2026 · Richard E. Pratley, Douglas Scott Denham, et al. · Nature Medicine · 26
PDF
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor‐1 (PAI‐1)
2004 · H.R. Lijnen, B. Van Hoef, et al. · Journal of Thrombosis and Haemostasis · 26
Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta
2016 · Lahar Mehta, Kimberly Umans, et al. · International Journal of MS Care · 9
PDF
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta
2017 · Gavin Giovannoni, Heinz Wiendl, et al. · Multiple Sclerosis Journal · 4
Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study (P07.105)
2013 · Eva Havrdova, Gavin Giovannoni, et al. · Neurology · 3
Long-Term Safety of Daclizumab HYP in Patients with Relapsing-Remitting Multiple Sclerosis: 3-4 Year Results from the SELECTED Extension Study (P7.225)
2015 · Ralf Gold, Gavin Giovannoni, et al. · Neurology · 2
Daclizumab HYP Monotherapy Improved Health-Related Quality of Life Parameters in Relapsing-Remitting Multiple Sclerosis: Findings of the SELECT Trial (P07.098)
2012 · K. Selmaj, E. Havrdova, et al. · Neurology · 2
Considerations for the real‐world management of ARIA from the aducanumab phase 3 studies EMERGE and ENGAGE
2021 · Patrick Burkett, Spyros Chalkias, et al. · Alzheimer s & Dementia · 1
578PTreatment effects and perceptions among apitegromab-treated patients with type 2/3 spinal muscular atrophy: patient and caregiver interviews from the TOPAZ clinical trial
2025 · M. Gueye, E. Mazzone, et al. · Neuromuscular Disorders
Considerations for the Real-World Management of ARIA From the Aducanumab Phase 3 Studies EMERGE and ENGAGE (P1-1.Virtual)
2022 · Richard Hughes, Patrick Burkett, et al. · Neurology
Return of MS Disease Activity after Daclizumab Discontinuation Did Not Exceed Baseline Levels in SELECT/SELECTION Studies (P2.400)
2017 · Gavin Giovannoni, Augusto Miravalle, et al. · Neurology
Additional file 1: Table S1. of Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
2016 · Gold, Ralf, Radue, Ernst-Wilhelm, et al. · Figshare
Works count: 19
Citation count: 912
H-index: 8
I10-index: 7
Year
Topic
Type